Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Study of Domatinostat (4SC-202) in Combination with avelumab Refractory Patients with Advanced Merkel Cell Carcinoma (MCC)

Trial Profile

A Pivotal Study of Domatinostat (4SC-202) in Combination with avelumab Refractory Patients with Advanced Merkel Cell Carcinoma (MCC)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Domatinostat (Primary)
  • Indications Merkel cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms MERKLIN 2
  • Sponsors 4SC
  • Most Recent Events

    • 21 Oct 2019 According to a 4SC media release, design of MERKLIN 1 and MERKLIN 2 studies will be presented at the 1st International Symposium on Merkel Cell Carcinoma by Dr. Rene Bartz. The trial is planned to initiate in Q4,2020.
    • 08 Aug 2019 According to a 4SC media release, the company plans to start this trial in late 2019.
    • 08 Aug 2019 According to a 4SC media release, initial top-line data is expected in the first half of 2021
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top